Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT 1F receptor inhibitory effects on trigeminal neurons with craniovascular input

Neuroscience

Volumn 122, Issue 2, 2003, Pages 491-498

  Goadsby, P J ^a   Classey, J D ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Headache; Migraine; Pathophysiology; Serotonin receptor; Sumatriptan

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; ALNIDITAN; CHLORALOSE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; NARATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1F AGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY FLOW; CAT; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE;

EID: 0242660235     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00570-0     Document Type: Article

References (61)

1. Anthony M., Hinterberger H., Lance J.W. Plasma serotonin in migraine and stress. Arch Neurol. 16:1967;544-552.
2. Boers P., Donaldson C., Zagami A.S., Lambert G.A. 5-HT1A and 5-HT1B/1D receptors are involved in the modulation of the trigeminovascular system of the cat a microiontophoretic study . Neuropharmacology. 39:2000;1833-1847.
3. Bomhof M., Paz J., Legg N., Allen C., Vandormael K., Patel K. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine. Eur Neurol. 42:2000;173-179.
4. Bond R.F. "In" vivo method for calibrating electromagnetic flowmeter probes. J Appl Physiol. 22:1967;358-361.
5. 1F rececptor agonists in human and bovine cerebral arteries similarity with human coronary artery . Br J Pharmacol. 129:2000;501-508.
6. 1F receptor expression in rat trigeminal ganglion (TRG) and dorsal root ganglia (DRG) neurons. Cephalalgia. 22:2002;595-596.
7. 1D antagonists. J Med Chem. 37:1994;2253-2257.
8. Cohen M. Multiple microvascular and astroglial 5HT receptor subtypes in human brain molecular and pharmacological characterization . J Cereb Blood Flow Metab. 19:1999;908-917.
9. Cohen M.L., Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein . J Pharmacol Exp Ther. 290:1999;935-939.
10. Connor H.E., Feniuk W., Beattie D.T., North P.C., Oxford A.W., Saynor D.A., Humphrey P.P.A. Naratriptan biological profile in animal models relevant to migraine . Cephalalgia. 17:1997;145-152.
11. Cumberbatch M.J., Hill R.G., Hargreaves R.J. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 328:1997;37-40.
12. 1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia. 18:1998;659-664.
13. 1D agonist. Cephalalgia. 20:2000;268.
14. 1D (BRL15572) receptor antagonists . Eur J Pharmacol. 362:1998;69-72.
15. 1B/1D and novel receptors . Br J Pharmacol. 123:1998;1561-1570.
16. De Vries P., Villalon C.M., Saxena P.R. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol. 375:1999;61-74.
17. Ferrari M.D. Migraine. Lancet. 351:1998;1043-1051.
18. 1B/1D agonists) in migraine methods and detailed results of a meta-analysis of 53 trials . Cephalalgia. 22:2002;633-658.
19. Fleishaker J.C., Pearson L.K., Knuth D.W., Gomez-Mancilla B., Francom S.F., McIntosh M.J., Freestone S., Azie N.E. Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU- 142633F. Int J Clin Pharmacol Ther. 37:1999;487-492.
20. 1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia. 23:2003;287-292.
21. Goadsby P.J. The pharmacology of headache. Prog Neurobiol. 62:2000;509-525.
22. 1) receptors in the trigeminocervical complex. Ann Neurol. 50:2001;804-807.
23. Goadsby P.J., Hoskin K.L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90) are brain stem sites a therapeutic target in migraine? Pain. 67:1996;355-359.
24. 1B/1D receptor a central action in migraine? Ann Neurol. 43:1998;711-718.
25. Goadsby P.J., Hoskin K.L. Differential effects of low dose CP122, 288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in the cat. Pain. 82:1999;15-22.
26. Goadsby P.J., Hoskin K.L., Storer R.J., Edvinsson L., Connor H.E. Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain. 125:2002;1392-1401.
27. 1B/1D) receptors. Br J Pharmacol. 122:1997;918-922.
28. Goadsby P.J., Lambert G.A., Lance J.W. Effects of locus coeruleus stimulation on carotid vascular resistance in the cat. Brain Res. 278:1983;175-183.
29. Goadsby P.J., Lipton R.B., Ferrari M.D. Migraine current understanding and treatment . N Engl J Med. 346:2002;257-270.
30. Goldstein D.J., Gossen D., Granier L. Clinical experience with LY334370, a selective serotonin 1F receptor agonist (SSOFRA) absence of cardiovascular effects . Cephalalgia. 19:1999;366-367.
31. 1F receptor agonist (SSOFRA) LY334370. Cephalalgia. 19:1999;318.
32. Hoskin K.L., Kaube H., Goadsby P.J. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain. 119:1996;1419-1428.
33. Hu J.W., Dostrovsky J.O., Sessle B.J. Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn) I. Responses to oral-facial noxious and nonnoxious stimuli and projections to thalamus and subnucleus oralis . J Neurophysiol. 45:1981;173-191.
34. Humphrey P.P.A., Feniuk W., Perren M.J., Beresford I.J.M., Skingle M., Whalley E.T. Serotonin and migraine. Ann NY Acad Sci. 600:1990;587-598.
35. Humphrey P.P.A., Goadsby P.J. Controversies in headache the mode of action of sumatriptan is vascular? a debate . Cephalalgia. 14:1994;401-410.
36. Kaube H., Hoskin K.L., Goadsby P.J. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia. 12:1992;133-136.
37. Kaube H., Keay K.A., Hoskin K.L., Bandler R., Goadsby P.J. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 629:1993;95-102.
38. Kimball R.W., Friedman A.P., Vallejo E. Effect of serotonin in migraine patients. Neurology. 10:1960;107-111.
39. 3H]alniditan . Mol Pharmacol. 50:1996;1567-1580.
40. Longmore J., Shaw D., Smith D., Hopkins R., McAllister G., Pickard J.D., Sirinathsinghji D.J.S., Butler A.J., Hill R.G. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system implications for the discovery of new antimigraine drugs . Cephalalgia. 17:1997;833-842.
41. 1B/1D/1F receptors and glutamate in trigeminal ganglion in rats. Neuroreport. 12:2001;1589-1591.
42. Moskowitz M.A., Cutrer F.M. Sumatriptan a receptor-targeted treatment for migraine . Annu Rev Med. 44:1993;145-154.
43. 1B receptors in human cerebral arteries pharmacological characterization and localization with immunocytochemistry . Br J Pharmacol. 128:1999;1133-1140.
44. Nilsson T., Longmore J., Shaw D., Pantev E., Bard J.A., Branchek T., Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 372:1999;49-56.
45. Pascual J., Vega P., Diener H.-C., Allen C., Vrijens F., Patel K. Comparison of rizatriptan 10mg versus zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia. 20:1999;455-461.
46. 1Dα receptor sites. Neuropharmacology. 34:1995;235-237.
47. 1D binding sites. Eur J Pharmacol. 163:1989;133-136.
48. Pregenzer J.F., Alberts G.L., Block J.H., Slightom J.L., Im W.B. Characterisation of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci Lett. 235:1997;117-120.
49. 1D-selective ligands). Br J Pharmacol. 127:1999;468-472.
50. 1D receptors. Naunyn-Schmiedebergs Arch Pharmacol. 356:1997;312-320.
51. 1F- receptor activation . Br J Clin Pharmacol. 47:1999;75-82.
52. Rebeck G.W., Maynard K.I., Hyman B.T., Moskowitz M.A. Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglion implications for antimigraine drug development . Proc Natl Acad Sci USA. 91:1994;3666-3669.
53. Selkirk J.V., Scott C., Ho M., Burton M.J., Watson J., Gaster L.M., Collin L., Jones B.J., Middlemiss D.N., Price G.W. SB-224289 a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity . Br J Pharmacol. 125:1998;202-208.
54. 1F receptor agonist LY334370. Cephalalgia. 19:1999;851-858.
55. Siegel S. Non-parametric statistics for the behavioural sciences. 1956;McGraw-Hill, Kogakusha, Tokyo.
56. Smith D., Shaw D., Hopkins R., McAllister G., Hill R., Sirinathsinghji D., Longmore J. Development and characterisation of human 5-HT1B- or 5-HT1D-receptor specific antibodies as unique research tools. J Neurosci Methods. 80:1998;155-161.
57. 1B/1D) agonist doses. Neuropharmacology. 40:2001;911-917.
58. Storer R.J., Butler P., Hoskin K.L., Goadsby P.J. A simple method, using 2-hydroxypropyl-β-cyclodextrin, of administering α-chloralose at room temperature. J Neurosci Methods. 77:1997;49-53.
59. 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain. 120:1997;2171-2177.
60. 1D receptor antagonists and in situ hybridization. Cephalalgia. 22:2002;83-93.
61. Welch K.M.A., Mathew N.T., Stone P., Rosamond W., Saiers J., Gutterman D. Tolerability of sumatriptan clinical trials and post-marketing experience . Cephalalgia. 20:2000;687-694.